Low-Dose Lithium for Alzheimer's Disease
Also known as: Lithium orotate, Lithium aspartate, Microdose lithium
Lithium is the most established GSK3β inhibitor, and GSK3β overactivity drives tau hyperphosphorylation in Alzheimer's.
Mechanism of Action
Lithium inhibits GSK3β, directly reducing tau phosphorylation at key epitopes. It promotes autophagy for amyloid clearance, enhances BDNF for synaptic plasticity, and inhibits amyloid-beta production by reducing γ-secretase activity. Trace lithium in water correlates with reduced dementia.
General mechanism: GSK3β inhibitor. Autophagy inducer (IP3 pathway). BDNF/GDNF enhancer. Neuroprotective at microdoses.
Current Evidence
Epidemiological studies show areas with higher water lithium have lower dementia rates. Microdose lithium (300μg) showed cognitive stabilization in AD patients (Nunes et al., 2013). Low-dose approach promising.
Clinical Status: Epidemiological and clinical support for low-dose use. Standard-dose studies limited by side effects.
Safety Profile
Microdose (<1mg): very safe. Standard dose (600-1200mg): renal, thyroid toxicity requiring monitoring. Narrow therapeutic index at psychiatric doses.
Key Research Questions
- Can trace-dose lithium prevent AD in at-risk populations?
- What lithium dose optimally inhibits GSK3β without side effects?